KR102302392B1 - 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 - Google Patents

항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 Download PDF

Info

Publication number
KR102302392B1
KR102302392B1 KR1020207019525A KR20207019525A KR102302392B1 KR 102302392 B1 KR102302392 B1 KR 102302392B1 KR 1020207019525 A KR1020207019525 A KR 1020207019525A KR 20207019525 A KR20207019525 A KR 20207019525A KR 102302392 B1 KR102302392 B1 KR 102302392B1
Authority
KR
South Korea
Prior art keywords
seq
leu
arg
ala
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207019525A
Other languages
English (en)
Korean (ko)
Other versions
KR20200085927A (ko
Inventor
김상재
김경희
이규용
고성호
김범준
박현희
허성진
이우진
장화인
하정순
Original Assignee
주식회사 젬백스앤카엘
김상재
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020120079096A external-priority patent/KR20140012385A/ko
Priority claimed from KR1020120089162A external-priority patent/KR20140022698A/ko
Priority claimed from KR1020120089167A external-priority patent/KR20140022699A/ko
Application filed by 주식회사 젬백스앤카엘, 김상재 filed Critical 주식회사 젬백스앤카엘
Publication of KR20200085927A publication Critical patent/KR20200085927A/ko
Application granted granted Critical
Publication of KR102302392B1 publication Critical patent/KR102302392B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
KR1020207019525A 2012-07-20 2013-03-15 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물 Active KR102302392B1 (ko)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
KR1020120079096 2012-07-20
KR1020120079096A KR20140012385A (ko) 2012-07-20 2012-07-20 항염증 활성을 갖는 펩티드 및 이를 포함하는 염증질환 치료용 조성물
KR20120089161 2012-08-14
KR1020120089167 2012-08-14
KR1020120089162 2012-08-14
KR1020120089162A KR20140022698A (ko) 2012-08-14 2012-08-14 텔로머라제 펩티드를 포함하는 염증 예방 또는 억제용 조성물
KR1020120089161 2012-08-14
KR1020120089167A KR20140022699A (ko) 2012-08-14 2012-08-14 텔로머라제 펩티드를 포함하는 염증 예방 또는 억제용 조성물
KR20120104144 2012-09-19
KR1020120104207 2012-09-19
KR1020120104144 2012-09-19
KR20120104207 2012-09-19
KR1020147034319A KR20150031413A (ko) 2012-07-20 2013-03-15 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
PCT/EP2013/055326 WO2014012683A1 (en) 2012-07-20 2013-03-15 Anti-inflammatory peptides and composition comprising the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147034319A Division KR20150031413A (ko) 2012-07-20 2013-03-15 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물

Publications (2)

Publication Number Publication Date
KR20200085927A KR20200085927A (ko) 2020-07-15
KR102302392B1 true KR102302392B1 (ko) 2021-09-16

Family

ID=47882177

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207019525A Active KR102302392B1 (ko) 2012-07-20 2013-03-15 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
KR1020147034319A Ceased KR20150031413A (ko) 2012-07-20 2013-03-15 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147034319A Ceased KR20150031413A (ko) 2012-07-20 2013-03-15 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물

Country Status (8)

Country Link
US (6) US20150125438A1 (enExample)
EP (3) EP3428182B1 (enExample)
JP (6) JP6352911B2 (enExample)
KR (2) KR102302392B1 (enExample)
CN (3) CN109777791B (enExample)
ES (3) ES2871899T3 (enExample)
TW (6) TWI779287B (enExample)
WO (1) WO2014012683A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320058D0 (en) 1993-09-29 1993-11-17 Gillette Co Savety razors
CN104507961B (zh) 2012-05-11 2018-08-14 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
ES2981865T3 (es) 2012-07-11 2024-10-10 Gemvax & Kael Co Ltd Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
CN110074997B (zh) 2012-09-19 2022-07-08 珍白斯凯尔有限公司 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
CN104981478B (zh) 2012-09-19 2019-02-22 珍白斯凯尔有限公司 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
AU2014236949C1 (en) * 2013-03-15 2018-11-29 Promega Corporation Activation of bioluminescence by structural complementation
JP6059405B2 (ja) 2013-06-07 2017-01-11 ジェムバックス アンド カエル カンパニー，リミティド 癌の免疫学的治療に有用な生物学的マーカー
WO2014204281A1 (ko) 2013-06-21 2014-12-24 주식회사 카엘젬백스 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
KR102224965B1 (ko) * 2013-07-12 2021-03-09 주식회사 젬백스앤카엘 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
KR102359396B1 (ko) 2013-11-22 2022-02-08 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
US11058744B2 (en) 2013-12-17 2021-07-13 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
JP6420459B2 (ja) * 2014-04-11 2018-11-07 ジェムバックス アンド カエル カンパニー，リミティド 線維症抑制活性を有するペプチド及びこれを含む組成物
CN106659149B (zh) * 2014-04-30 2020-05-19 珍白斯凯尔有限公司 用于器官、组织或细胞移植的组合物、试剂盒和移植方法
EP3193906B1 (en) * 2014-09-18 2020-11-11 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of Holy and Undiv. Trinity of Queen Elizabeth near Dublin Use of peptide inhibitors of il-36 proteolytic processing for the treatment and/or reduction of inflammation
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
JP6751097B2 (ja) 2015-02-27 2020-09-02 ジェムバックス アンド カエル カンパニー，リミティド 聴力損傷予防用ペプチド及びそれを含む組成物
KR101662438B1 (ko) * 2015-04-07 2016-10-04 가톨릭대학교 산학협력단 X형 구조의 dna를 유효성분으로 포함하는 아토피 피부염 예방 또는 치료용 조성물
KR101734529B1 (ko) 2015-05-08 2017-05-11 건국대학교 산학협력단 패혈증 치료제의 스크리닝 방법 및 패혈증 치료용 약학 조성물
KR102911237B1 (ko) 2015-05-26 2026-01-13 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
EP3318265B1 (en) 2015-07-02 2021-08-18 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
US10858397B2 (en) 2015-08-28 2020-12-08 The Medical College Of Wisconsin, Inc. Peptide inhibitors of telomerase translocation and therapeutic uses thereof
CA3006044A1 (en) * 2015-09-09 2017-03-16 uBiome, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with cerebro-craniofacial health
EP4272829A3 (en) * 2016-04-07 2024-01-17 Gemvax & Kael Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
KR101831888B1 (ko) * 2016-04-15 2018-04-16 (주)케어젠 항염증 활성을 갖는 펩타이드 및 이의 용도
KR101887577B1 (ko) * 2016-10-19 2018-09-10 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
ES2932772T3 (es) * 2016-12-22 2023-01-26 Univ Montpellier Nuevos péptidos grapados y utilizaciones de los mismos
JP6601849B2 (ja) * 2017-08-21 2019-11-06 株式会社大一商会 遊技機
JP6601848B2 (ja) * 2017-08-21 2019-11-06 株式会社大一商会 遊技機
KR102092843B1 (ko) * 2018-08-30 2020-03-24 충남대학교 산학협력단 암 예방 또는 치료용 펩타이드 및 이의 용도
KR102274658B1 (ko) * 2018-11-16 2021-07-09 주식회사 카인사이언스 염증성 피부질환 치료용 펩타이드 및 이의 용도
KR102032945B1 (ko) * 2018-12-03 2019-10-16 순천대학교 산학협력단 항염증 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항염증용 조성물
KR102146937B1 (ko) * 2018-12-11 2020-08-21 대한민국 왕사마귀로부터 유래된 테노데라신-1 펩타이드, 이를 유효성분으로 포함하는 항균, 항진균 또는 항염증용 조성물
KR102266613B1 (ko) * 2020-09-21 2021-06-18 자안바이오 주식회사 항염증 활성을 갖는 신규한 펩티드 및 이의 용도
WO2022167656A1 (en) * 2021-02-08 2022-08-11 Bacoba Ag Treatment of skin disorders
WO2023214802A1 (ko) * 2022-05-03 2023-11-09 한국생명공학연구원 신규 펩타이드 및 이의 항염 및 재생 용도
KR102827929B1 (ko) * 2023-01-26 2025-07-09 ㈜에빅스젠 신규한 뇌 질환 치료제 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002581A1 (en) 1998-07-08 2000-01-20 Norsk Hydro Asa Antigenic peptides derived from telomerase
WO2009025871A1 (en) 2007-08-23 2009-02-26 University Of Medicine And Dentistry Of Nj Telomerase reverse transcriptase variant
WO2010003520A2 (en) 2008-06-16 2010-01-14 Genovax S.R.L. Anti-tumor immunotherapy
WO2011101173A1 (en) * 2010-02-16 2011-08-25 Oslo University Hospital Hf Polypeptides

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523965A (en) * 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
DE4330664A1 (de) * 1993-09-10 1995-03-16 Beiersdorf Ag Verwendungen von Pflanzenölen
CZ3497A3 (en) * 1994-07-07 1997-10-15 Geron Corp Rna component of mammal telomerase, oligonucleotide, recombinant expression plasmid containing the oligonucleotide, process for preparing eukaryotic host cell, process for preparing a recombinant telomerase enzyme
EP0912558B1 (en) * 1996-06-25 2003-07-09 Pfizer Inc. Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors
US6610839B1 (en) * 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
EP0841396B2 (en) * 1996-10-01 2012-04-11 Geron Corporation Human telomerase catalytic subunit
EP0917579A1 (en) * 1997-07-01 1999-05-26 Cambia Biosystems LLC Vertebrate telomerase genes and proteins and uses thereof
US20030171280A1 (en) * 2001-07-31 2003-09-11 Soderstrom Karl Petter Compositions and methods for modulation of immune responses
EP1421111A2 (en) * 2001-08-08 2004-05-26 Incyte Genomics, Inc. Proteins associated with cell growth differentiation, and death
US8492438B2 (en) * 2002-04-26 2013-07-23 Asan Laboratories Company (Cayman), Limited Treatment skin disorders
CA2524912A1 (en) * 2003-05-01 2004-11-18 Musc Foundation For Research Development An autologous upregulation mechanism allowing optimized cell type-specific and regulated gene expression cells
CN101011571A (zh) * 2006-03-13 2007-08-08 上海交通大学医学院 GADD45 β 蛋白及其抑制剂在类风湿关节炎中的应用
EP2089423B1 (en) * 2006-09-21 2016-10-26 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
ATE534661T1 (de) * 2006-10-12 2011-12-15 Angeletti P Ist Richerche Bio Fusionsprotein aus telomerase und reverser transkriptase, dafür codierende nukleotide und anwendungen davon
MX2009012470A (es) 2007-05-18 2010-02-24 Inhibox Ltd Compuestos de acido biciclosulfonilo y su uso como agentes terapeuticos.
GB2455539B (en) 2007-12-12 2012-01-18 Cambridge Entpr Ltd Anti-inflammatory compositions and combinations
US8252282B2 (en) * 2008-06-19 2012-08-28 University Of Medicine & Dentistry Of New Jersey Nuclear telomerase reverse transcriptase variant
JP5337809B2 (ja) 2008-09-22 2013-11-06 日清ファルマ株式会社 抗炎症性ペプチド
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
KR101284772B1 (ko) 2011-05-24 2013-07-17 정종문 항염증, 진통효과를 가지는 기능성 식품 조성물
KR20120133661A (ko) 2011-05-31 2012-12-11 주식회사 바이오포트코리아 아스타잔틴을 포함하는 항염증제
CN104507961B (zh) 2012-05-11 2018-08-14 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
WO2014046481A1 (ko) 2012-09-19 2014-03-27 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
CN104981478B (zh) 2012-09-19 2019-02-22 珍白斯凯尔有限公司 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
CN110074997B (zh) 2012-09-19 2022-07-08 珍白斯凯尔有限公司 细胞穿透肽、包含该肽的缀合物、及包含该缀合物的组合物
JP6059405B2 (ja) * 2013-06-07 2017-01-11 ジェムバックス アンド カエル カンパニー，リミティド 癌の免疫学的治療に有用な生物学的マーカー
KR102224965B1 (ko) 2013-07-12 2021-03-09 주식회사 젬백스앤카엘 세포 투과성 펩티드 및 이를 포함하는 컨쥬게이트
KR102911237B1 (ko) 2015-05-26 2026-01-13 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
WO2017066349A1 (en) 2015-10-13 2017-04-20 Symic Ip, Llc Ve-cadherin binding bioconjugate

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002581A1 (en) 1998-07-08 2000-01-20 Norsk Hydro Asa Antigenic peptides derived from telomerase
JP2002520293A (ja) 1998-07-08 2002-07-09 ノルスク・ヒドロ・アーエスアー テロメラーゼ由来抗原ペプチド
JP5491315B2 (ja) 1998-07-08 2014-05-14 ゲムヴァックス・アーエス テロメラーゼ由来抗原ペプチド
WO2009025871A1 (en) 2007-08-23 2009-02-26 University Of Medicine And Dentistry Of Nj Telomerase reverse transcriptase variant
WO2010003520A2 (en) 2008-06-16 2010-01-14 Genovax S.R.L. Anti-tumor immunotherapy
WO2011101173A1 (en) * 2010-02-16 2011-08-25 Oslo University Hospital Hf Polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Godet Y. et al, Clin Cancer Res*

Also Published As

Publication number Publication date
ES2693321T3 (es) 2018-12-11
EP3896078A1 (en) 2021-10-20
EP2875042A1 (en) 2015-05-27
CN109777791A (zh) 2019-05-21
EP3428182B1 (en) 2021-04-21
CN104470947B (zh) 2019-03-08
KR20200085927A (ko) 2020-07-15
TWI779287B (zh) 2022-10-01
JP2021011502A (ja) 2021-02-04
US20150125438A1 (en) 2015-05-07
CN117551631A (zh) 2024-02-13
TW202033540A (zh) 2020-09-16
EP2875042B1 (en) 2018-08-08
TWI658141B (zh) 2019-05-01
CN109777791B (zh) 2023-12-01
KR20150031413A (ko) 2015-03-24
JP7440581B2 (ja) 2024-02-28
TW202417473A (zh) 2024-05-01
TW201938579A (zh) 2019-10-01
US20200208127A1 (en) 2020-07-02
TWI647311B (zh) 2019-01-11
EP3896078C0 (en) 2025-11-19
WO2014012683A1 (en) 2014-01-23
JP2022166225A (ja) 2022-11-01
US20210388328A1 (en) 2021-12-16
CN104470947A (zh) 2015-03-25
US20240158768A1 (en) 2024-05-16
US20170275603A1 (en) 2017-09-28
JP7128246B2 (ja) 2022-08-30
JP2017158561A (ja) 2017-09-14
TWI836435B (zh) 2024-03-21
JP2024056904A (ja) 2024-04-23
JP7741218B2 (ja) 2025-09-17
TW202237629A (zh) 2022-10-01
JP2015525768A (ja) 2015-09-07
EP3428182A3 (en) 2019-02-27
US20200140832A1 (en) 2020-05-07
ES2871899T3 (es) 2021-11-02
JP6352911B2 (ja) 2018-07-04
ES3055196T3 (en) 2026-02-10
TWI700290B (zh) 2020-08-01
JP2019151638A (ja) 2019-09-12
EP3428182A2 (en) 2019-01-16
JP6788062B2 (ja) 2020-11-18
JP6514259B2 (ja) 2019-05-15
US11905536B2 (en) 2024-02-20
TW201406957A (zh) 2014-02-16
US11098294B2 (en) 2021-08-24
TW201742921A (zh) 2017-12-16
EP3896078B1 (en) 2025-11-19

Similar Documents

Publication Publication Date Title
KR102302392B1 (ko) 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
US12171812B2 (en) Anti-inflammatory peptides and composition comprising the same
KR102307567B1 (ko) 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200706

Application number text: 1020147034319

Filing date: 20141205

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200924

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210628

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210909

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210909

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240619

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20250619

Start annual number: 5

End annual number: 5